Alphamab Oncology (9966) Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 9966 from our risk checks.
9966 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alphamab Oncology Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.32 |
| 52 Week High | HK$15.75 |
| 52 Week Low | HK$6.01 |
| Beta | 0.49 |
| 1 Month Change | -14.49% |
| 3 Month Change | -12.34% |
| 1 Year Change | 5.63% |
| 3 Year Change | -0.14% |
| 5 Year Change | -70.78% |
| Change since IPO | -45.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9966 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 1.7% | -0.7% | -0.7% |
| 1Y | 5.6% | -10.7% | 3.9% |
Return vs Industry: 9966 exceeded the Hong Kong Biotechs industry which returned -10.7% over the past year.
Return vs Market: 9966 exceeded the Hong Kong Market which returned 3.9% over the past year.
Price Volatility
| 9966 volatility | |
|---|---|
| 9966 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.0% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 9966 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9966's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 498 | Ting Xu | www.alphamabonc.com |
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.
Alphamab Oncology Fundamentals Summary
| 9966 fundamental statistics | |
|---|---|
| Market cap | HK$6.92b |
| Earnings (TTM) | -HK$132.07m |
| Revenue (TTM) | HK$656.32m |
Is 9966 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9966 income statement (TTM) | |
|---|---|
| Revenue | CN¥566.24m |
| Cost of Revenue | CN¥63.55m |
| Gross Profit | CN¥502.69m |
| Other Expenses | CN¥616.63m |
| Earnings | -CN¥113.94m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 88.78% |
| Net Profit Margin | -20.12% |
| Debt/Equity Ratio | 6.9% |
How did 9966 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/18 03:11 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alphamab Oncology is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wangbin Zhou | Citigroup Inc |
| null null | CLSA |
| null null | Guoyuan Securities (HK) Ltd |